JP2024514844A - Ｍｙｔ１阻害剤を含む併用治療 - Google Patents
Ｍｙｔ１阻害剤を含む併用治療 Download PDFInfo
- Publication number
- JP2024514844A JP2024514844A JP2023561783A JP2023561783A JP2024514844A JP 2024514844 A JP2024514844 A JP 2024514844A JP 2023561783 A JP2023561783 A JP 2023561783A JP 2023561783 A JP2023561783 A JP 2023561783A JP 2024514844 A JP2024514844 A JP 2024514844A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- optionally substituted
- acceptable salt
- inhibitors
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171955P | 2021-04-07 | 2021-04-07 | |
| US63/171,955 | 2021-04-07 | ||
| PCT/CA2022/050536 WO2022213204A1 (en) | 2021-04-07 | 2022-04-07 | Combination therapies including myt1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514844A true JP2024514844A (ja) | 2024-04-03 |
| JP2024514844A5 JP2024514844A5 (https=) | 2025-04-03 |
| JPWO2022213204A5 JPWO2022213204A5 (https=) | 2025-04-03 |
Family
ID=83544890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561783A Pending JP2024514844A (ja) | 2021-04-07 | 2022-04-07 | Ｍｙｔ１阻害剤を含む併用治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240207300A1 (https=) |
| EP (1) | EP4319752A4 (https=) |
| JP (1) | JP2024514844A (https=) |
| CN (1) | CN117729920A (https=) |
| CA (1) | CA3214900A1 (https=) |
| WO (1) | WO2022213204A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435090B2 (en) | 2021-10-04 | 2025-10-07 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use |
| CN119451958A (zh) * | 2022-07-12 | 2025-02-14 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| KR20250094718A (ko) * | 2022-11-08 | 2025-06-25 | 제노 매니지먼트, 인크. | Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도 |
| WO2024104282A1 (zh) * | 2022-11-14 | 2024-05-23 | 捷思英达控股有限公司 | 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用 |
| EP4624471A4 (en) * | 2022-11-25 | 2026-03-18 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | PKMYT1 INHIBITOR, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND ITS USE |
| JP2025542335A (ja) * | 2022-12-22 | 2025-12-25 | リペア セラピューティクス インコーポレイテッド | Ｍｙｔ１阻害剤である２－アミノ－１－（３－ヒドロキシ－２，６－ジメチルフェニル）－５，６－ジメチル－１Ｈ－ピロロ－［２，３－ｂ］ピリジン－３－カルボキサミドを作製する方法 |
| WO2024153249A1 (zh) * | 2023-01-20 | 2024-07-25 | 杭州英创医药科技有限公司 | 作为pkmyt1抑制剂的化合物 |
| WO2024160683A1 (en) * | 2023-01-30 | 2024-08-08 | Ecole Polytechnique Federale De Lausanne (Epfl) | Pou5f1b inhibitors |
| WO2024179948A1 (en) * | 2023-02-28 | 2024-09-06 | F. Hoffmann-La Roche Ag | Indazole compounds as pkmyt1 kinase inhibitors |
| AU2024231943A1 (en) * | 2023-03-09 | 2025-10-16 | Cancer Research Technology Limited | Biarylamide derivatives and their use as pkmyt1 inhibitors |
| TW202444721A (zh) * | 2023-05-12 | 2024-11-16 | 智擎生技製藥股份有限公司 | 稠合吡咯環或稠合吡啶環之化合物 |
| CN121358735A (zh) * | 2023-07-04 | 2026-01-16 | 杭州领业医药科技有限公司 | Rp-6306的晶型及其制备方法和用途 |
| WO2025040014A1 (zh) * | 2023-08-18 | 2025-02-27 | 英矽智能科技知识产权有限公司 | 并环化合物及其制备方法和用途 |
| IL326854A (en) * | 2023-09-14 | 2026-04-01 | Debiopharm Int Sa | Combination of WEE1 inhibitor and PKMYT1 inhibitor |
| WO2025060975A1 (en) * | 2023-09-18 | 2025-03-27 | Insilico Medicine Ip Limited | Novel compounds as pkmyt1 inhibitors and use thereof |
| WO2025074271A1 (en) * | 2023-10-02 | 2025-04-10 | Repare Therapeutics Inc. | Myt1 inhibitors for the treatment of cancers harboring replication stress mutations |
| WO2025074275A1 (en) * | 2023-10-02 | 2025-04-10 | Repare Therapeutics, Inc. | Combination therapies including myt1 inhibitors and wee1 inhibitors |
| WO2025106635A1 (en) * | 2023-11-15 | 2025-05-22 | Zeno Management, Inc. | Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors |
| KR20250088374A (ko) * | 2023-12-08 | 2025-06-17 | 인제대학교 산학협력단 | Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물 |
| WO2025182927A1 (ja) * | 2024-02-27 | 2025-09-04 | 中外製薬株式会社 | Ｍｙｔ１阻害剤の用途 |
| WO2025188680A1 (en) * | 2024-03-04 | 2025-09-12 | Cardiff Oncology, Inc. | Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma |
| WO2025237957A1 (en) * | 2024-05-14 | 2025-11-20 | Institut Curie | Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor |
| US20260034078A1 (en) | 2024-07-31 | 2026-02-05 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud | Xpg inhibitor compounds and the use thereof in the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000033837A2 (en) * | 1998-12-07 | 2000-06-15 | Smithkline Beecham Corporation | Myt1 kinase inhibitors |
| WO2016104777A1 (ja) * | 2014-12-26 | 2016-06-30 | 国立大学法人九州大学 | がんの処置のための方法 |
| CN115811976A (zh) * | 2020-04-01 | 2023-03-17 | 修复治疗公司 | 使用myt1抑制剂的方法 |
| BR112022019611A2 (pt) * | 2020-04-01 | 2022-11-29 | Repare Therapeutics Inc | Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso |
-
2022
- 2022-04-07 WO PCT/CA2022/050536 patent/WO2022213204A1/en not_active Ceased
- 2022-04-07 CN CN202280040614.5A patent/CN117729920A/zh active Pending
- 2022-04-07 US US18/284,614 patent/US20240207300A1/en active Pending
- 2022-04-07 JP JP2023561783A patent/JP2024514844A/ja active Pending
- 2022-04-07 EP EP22783740.8A patent/EP4319752A4/en active Pending
- 2022-04-07 CA CA3214900A patent/CA3214900A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240207300A1 (en) | 2024-06-27 |
| WO2022213204A1 (en) | 2022-10-13 |
| EP4319752A1 (en) | 2024-02-14 |
| CN117729920A (zh) | 2024-03-19 |
| CA3214900A1 (en) | 2022-10-13 |
| WO2022213204A9 (en) | 2023-11-16 |
| EP4319752A4 (en) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514844A (ja) | Ｍｙｔ１阻害剤を含む併用治療 | |
| JP7714570B2 (ja) | 化合物、医薬組成物、ならびに化合物の調製方法及び使用方法 | |
| US12435090B2 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | |
| US20230158022A1 (en) | Methods of using myt1 inhibitors | |
| KR102374844B1 (ko) | 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도 | |
| KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
| CN113474347A (zh) | Mat2a的aza杂双环抑制剂和用于治疗癌症的方法 | |
| US20230142913A1 (en) | Tricyclic heteroarenes, pharmaceutical compositions containing the same, and methods of using the same | |
| JP2024534659A (ja) | Ｎ－（５－置換［（１，３，４－チアジアゾリル）または（チアゾリル）］）（置換）カルボキサミド化合物、及びヒトポリメラーゼシータを阻害するためのその使用 | |
| CN107922431A (zh) | Hpk1抑制剂及其使用方法 | |
| JP2026506002A (ja) | Ｓｏｓ１阻害剤及び抗がん薬を含む、がんの処置のための医薬組成物 | |
| KR20240127909A (ko) | Sos1 억제제로서의 아졸릴피리딘 피리다지논 아미드 | |
| US20250304537A1 (en) | Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same | |
| WO2014079232A1 (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
| US20230348456A1 (en) | Quinazolinones, pharmaceutical compositions containing the same, and methods of using the same | |
| HK40108100A (zh) | 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途 | |
| EA052456B1 (ru) | Соединения, фармацевтические композиции, а также способы получения соединений и их применения | |
| EA050141B1 (ru) | Соединения, фармацевтические композиции, а также способы получения соединений и их применения | |
| HK40062088A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| WO2024249554A1 (en) | Multitarget small molecule inhibitors and uses thereof | |
| BR122024006404A2 (pt) | Compostos inibidores de tirosina e de cdc2 específica de treonina cinase e composição farmacêutica compreendendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250326 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250326 |